CD38 — Drug Target
All drugs that target CD38 — marketed and clinical-stage. Includes 10 drug classes acting on this target.
Drug classes
Monoclonal antibody · CD38-targeting monoclonal antibody · CD38-directed Cytolytic Antibody [EPC] · Monoclonal antibody (CD38-targeting) combined with corticosteroid · Monoclonal antibody with recombinant human hyaluronidase · Monoclonal antibody (CD38-targeting) · CD38-directed monoclonal antibody · Monoclonal antibody-drug conjugate · Monoclonal antibody, Proteasome inhibitor, Chemotherapy · CD38-targeting radioligand therapy
Marketed (5)
- Darzalex · Johnson & Johnson · Monoclonal antibody · Oncology
Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP. - DARATUMUMAB (DARZALEX®) · Hospices Civils de Lyon · CD38-targeting monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Darzalex Faspro · Pfizer · CD38-directed Cytolytic Antibody [EPC] · Oncology
Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells. - Daratumumab and corticosteroid treatment · Institute of Hematology & Blood Diseases Hospital, China · Monoclonal antibody (CD38-targeting) combined with corticosteroid · Oncology
Daratumumab binds to CD38 on multiple myeloma cells to trigger immune-mediated cell death, while corticosteroids provide immunosuppressive and anti-inflammatory support. - Daratumumab Hyaluronidase-fihj · Memorial Sloan Kettering Cancer Center · CD38-targeting monoclonal antibody · Oncology
Daratumumab binds to CD38 on multiple myeloma cells to trigger their destruction, while hyaluronidase enables faster subcutaneous administration by breaking down hyaluronic acid in tissue.
Phase 3 pipeline (12)
- Isatuximab IV · Sanofi · CD38-targeting monoclonal antibody · Oncology
Isatuximab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Daratumumab Injection · Charite University, Berlin, Germany · CD38-targeting monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of plasma cells and multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Daratumumab/rHuPH20 · Masonic Cancer Center, University of Minnesota · Monoclonal antibody with recombinant human hyaluronidase · Oncology
Daratumumab is a monoclonal antibody that targets CD38 on multiple myeloma cells, while rHuPH20 is a recombinant human hyaluronidase that enhances subcutaneous delivery by breaking down hyaluronic acid in the extracellular matrix. - Darzalex Faspro(Daratumumab) · Celltrion · Monoclonal antibody (CD38-targeting) · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Dara IV · Janssen Research & Development, LLC · CD38-targeting monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Daratumumab SC: daratumumab + rHuPH20 · Janssen Research & Development, LLC · CD38-targeting monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while rHuPH20 enhances subcutaneous bioavailability. - Dara SC · Janssen Research & Development, LLC · CD38-targeting monoclonal antibody · Oncology
Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Arm B: Daratumumab Hyaluronidase · PrECOG, LLC. · CD38-targeting monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while hyaluronidase enables subcutaneous administration by breaking down hyaluronic acid in subcutaneous tissue. - Daratumumab SC · Janssen Research & Development, LLC · CD38-directed monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - Daratumumab IV · Janssen Research & Development, LLC · CD38-targeting monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms. - CT-P44(Daratumumab) · Celltrion · CD38-targeting monoclonal antibody · Oncology
CT-P44 is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through antibody-dependent cellular cytotoxicity and direct apoptosis. - isatuximab SAR650984 · Sanofi · Monoclonal antibody · Oncology
Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of certain cancer cells.
Phase 2 pipeline (4)
- Daratumumab with dexamethasone · Hellenic Society of Hematology · Monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. - Daratumumab, Ixazomib, Dexamethasone · Hellenic Society of Hematology · Monoclonal antibody · Oncology
Daratumumab is a monoclonal antibody that targets CD38. - Daratumumab-hyaluronidase · Eastern Cooperative Oncology Group · Monoclonal antibody-drug conjugate · Oncology
Daratumumab-hyaluronidase is a monoclonal antibody-drug conjugate that targets CD38 on cancer cells. - Daratumumab plus Velcade Cyclophosphamide Dexamethasone · Stichting European Myeloma Network · Monoclonal antibody, Proteasome inhibitor, Chemotherapy · Oncology
Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells, while Velcade is a proteasome inhibitor that blocks the action of proteasomes, which are responsible for breaking down proteins in cells, and Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells.
Phase 1 pipeline (2)
- Actinium Ac 225-DOTA-Daratumumab · City of Hope Medical Center · CD38-targeting radioligand therapy · Oncology
Targeting CD38 with a radioligand - Anti-CD38 Monoclonal Antibody · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Monoclonal antibody · Oncology
Monoclonal antibody targeting CD38